| Nov 12 |
ProKidney GAAP EPS of -$0.14
|
| Nov 12 |
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
|
| Nov 7 |
ProKidney: Major Catalyst Is Too Far Away
|
| Nov 5 |
ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference
|
| Oct 22 |
Suvretta Capital Management's Strategic Acquisition in ProKidney Corp
|
| Oct 18 |
We're Not Very Worried About ProKidney's (NASDAQ:PROK) Cash Burn Rate
|
| Oct 14 |
ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2024
|
| Oct 9 |
ProKidney to Participate in the UBS Virtual Organ Restoration Day
|
| Sep 29 |
Wall Street Breakfast: The Week Ahead
|
| Sep 4 |
ProKidney drops Phase III CKD study to focus on US market and save up to $175m
|
